Klotho (Alpha-Klotho)
Low EvidenceA naturally occurring longevity hormone (secreted alpha-klotho) being studied for cognition and brain aging; a single low-dose injection improved memory in aged monkeys, and a first-in-human Phase 1 trial in older adults is underway.
What It Is
Klotho is a longevity protein the body makes naturally, named after the Greek Fate who spins the thread of life. The form most studied for brain aging is alpha-klotho (α-klotho), a hormone that is cleaved from a membrane-bound protein in the kidney and brain and released into the blood and cerebrospinal fluid, where it influences insulin, fibroblast growth factor (FGF), Wnt, and NMDA-receptor signaling. People who naturally carry the KL-VS genetic variant tend to have higher klotho levels and, on average, perform better on tests of memory and thinking, which is what first drew researchers to klotho as a target for healthy brain aging. In animals, raising klotho — genetically or by injecting the protein — improves synaptic plasticity, learning, and memory and adds resilience in models of Alzheimer's and Parkinson's disease. The landmark finding came in 2023, when a single low-dose (but, notably, not high-dose) injection of klotho enhanced memory in aged rhesus monkeys for up to about two weeks — even though klotho does not appear to cross the blood-brain barrier, implying it works through an indirect, downstream cascade rather than entering the brain directly. A 2025 meta-analysis of roughly 6,600 people reported a positive association between circulating klotho levels and cognitive performance. On the strength of this work, a UCSF team led by Dr. Dena Dubal has been moving a Phase 1 clinical trial forward to test whether a single low-dose injection of klotho can improve cognition in healthy older adults. Important context: klotho is a large protein, not a small synthetic peptide, and delivering it as a drug is technically difficult; it is investigational, is not approved by the FDA or any regulator, and is not a marketed, prescribed, or compounded product. Despite intense online interest, the klotho studied in these trials is not the same thing as the 'klotho' supplements or research chemicals sometimes sold to consumers.
Why Researchers Study It
Klotho is one of the most compelling targets in the science of brain aging because it links a natural longevity hormone to measurable differences in human cognition. People with higher klotho (including KL-VS variant carriers) tend to think and remember better, and in animals a single klotho injection can restore learning and memory even in old or disease-model brains — apparently without the protein entering the brain at all. Researchers want to know whether giving klotho to humans can replicate that benefit, how a peripherally injected protein produces central effects, and whether klotho could one day protect against age-related cognitive decline, Alzheimer's, or Parkinson's. It represents a fundamentally different approach from the metabolic (GLP-1/amylin) and tissue-repair peptides that dominate the field: a longevity-and-cognition mechanism rather than a weight or recovery one.
Proposed Mechanisms
- Circulates as a secreted hormone (alpha-klotho) after cleavage from a membrane-bound protein, acting on distant tissues including the brain
- Enhances synaptic plasticity and cognition through GluN2B-dependent NMDA-receptor signaling
- Modulates FGF23/FGF, insulin/IGF-1, and Wnt signaling pathways involved in aging
- Appears to act without crossing the blood-brain barrier, implying an indirect, downstream cascade rather than direct brain entry
- May modify APOE-associated Alzheimer's risk and add resilience to neurodegenerative stress in animal models
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (Phase 1, in progress) | First-in-human trial (UCSF, Dr. Dena Dubal) testing a single low-dose klotho injection for cognition in healthy older adults; cognitive testing over ~90 days | Designed to test whether exogenous klotho improves cognition; no efficacy results published yet | Source |
| Animal (non-human primate) | Aged rhesus macaques given a single injection of klotho (low vs high dose) | A single LOW dose (not high dose) enhanced memory for up to ~2 weeks despite klotho not crossing the blood-brain barrier | Source |
| Human (observational meta-analysis) | ~6,600 subjects pooled across studies (2025) | Positive association between circulating klotho levels and cognitive performance (correlational, not causal) | Source |
| Animal (rodent) | Mice injected with klotho, including aged and neurodegeneration models | Improved synaptic plasticity, spatial memory, and resilience; benefits from a single injection lasting weeks | Source |
Commonly Discussed Benefits
Researching Klotho (Alpha-Klotho)? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Investigational only — klotho is NOT approved by the FDA or any regulator for any use, and is not a marketed, prescribed, or compounded product
- Most evidence is from animals (mice and monkeys); the human Phase 1 trial is early and has no published efficacy results
- Klotho is a large protein, not a small synthetic peptide — it is hard to deliver as a drug and does not readily cross the blood-brain barrier
- In the monkey study, only the LOW dose helped and the HIGH dose did not — 'more' is not better, and human dosing is unknown
- Cognitive improvement is notoriously hard to measure in short trials, and animal results often fail to translate to humans
- Klotho affects the kidneys, mineral metabolism, and cardiovascular system; safety beyond cognition requires careful monitoring
- 'Klotho' products, peptides, or supplements sold online are not the clinical-grade protein being studied and are not a validated way to raise klotho or improve cognition
Comparisons
See how Klotho (Alpha-Klotho) compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Castner et al. — Longevity factor klotho enhances cognition in aged nonhuman primates (Nature Aging, 2023) PubMed
- [2] Is Klotho the key to brain resilience in aging? — Institute on Aging, University of Pennsylvania PubMed
- [3] KLOTHO-VS heterozygosity, α-klotho protein levels and cognitive performance (PMC, 2025) PubMed
Keep researching in the app
- Log Klotho (Alpha-Klotho) to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Epithalon
Low EvidenceA tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.
MOTS-c
Low EvidenceA mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.
Dihexa
Low EvidenceA hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation.
FOXO4-DRI
Low EvidenceA senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction.
Cerebrolysin
Medium EvidenceA porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.
NAD+
Medium EvidenceA coenzyme essential for cellular energy production, studied for anti-aging and metabolic support.
Humanin
Low EvidenceAn endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians.